<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>302(1)</volume><submitter>Edwards RL</submitter><pubmed_abstract>Polysaccharide protein conjugate vaccines consist of bacterial polysaccharides covalently linked to carrier proteins. Bioconjugate vaccines are a type of polysaccharide protein conjugate vaccine produced by oligosaccharyltransferases, which catalyze the en bloc transfer of polysaccharides to specific amino acid motifs, called sequons, engineered into carrier proteins. The O-linking oligosaccharyltransferase PglS has been shown to have the broadest substrate repertoire, transferring virtually any saccharide to engineered carrier proteins, making it an attractive bioconjugation tool for next generation vaccine development. Yet, the efficiency of glycan transfer varies depending on the polysaccharide substrate. Successful bioconjugation hinges upon the ability of an oligosaccharyltransferase </pubmed_abstract><journal>The Journal of biological chemistry</journal><pagination>110885</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12800693</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Enhancing O-linking oligosaccharyltransferase functionality through directed evolution.</pubmed_title><pmcid>PMC12800693</pmcid><pubmed_authors>McAllister KN</pubmed_authors><pubmed_authors>McGuffey JC</pubmed_authors><pubmed_authors>Scott NE</pubmed_authors><pubmed_authors>Knoot CJ</pubmed_authors><pubmed_authors>Harding CM</pubmed_authors><pubmed_authors>Hooppaw AJ</pubmed_authors><pubmed_authors>Zhou B</pubmed_authors><pubmed_authors>Mackel JJ</pubmed_authors><pubmed_authors>Edwards RL</pubmed_authors><pubmed_authors>Robinson LS</pubmed_authors></additional><is_claimable>false</is_claimable><name>Enhancing O-linking oligosaccharyltransferase functionality through directed evolution.</name><description>Polysaccharide protein conjugate vaccines consist of bacterial polysaccharides covalently linked to carrier proteins. Bioconjugate vaccines are a type of polysaccharide protein conjugate vaccine produced by oligosaccharyltransferases, which catalyze the en bloc transfer of polysaccharides to specific amino acid motifs, called sequons, engineered into carrier proteins. The O-linking oligosaccharyltransferase PglS has been shown to have the broadest substrate repertoire, transferring virtually any saccharide to engineered carrier proteins, making it an attractive bioconjugation tool for next generation vaccine development. Yet, the efficiency of glycan transfer varies depending on the polysaccharide substrate. Successful bioconjugation hinges upon the ability of an oligosaccharyltransferase </description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Nov</publication><modification>2026-06-06T14:53:20.316Z</modification><creation>2026-06-01T03:07:24.449Z</creation></dates><accession>S-EPMC12800693</accession><cross_references><pubmed>41203123</pubmed><doi>10.1016/j.jbc.2025.110885</doi></cross_references></HashMap>